Warner-Lambert/Neurex SNX-111 pivotal trial in head trauma suspends patient enrollment.

Executive Summary

WARNER-LAMBERT/NEUREX SNX-111 HEAD TRAUMA PHASE III ENROLLMENT SUSPENDED following unblinding of results from earlier trials, the companies announced July 28. The Phase III head trauma study was planned as an 800-patient trial but only a few subjects have been enrolled, Neurex said. The recently received data "must be carefully analyzed to evaluate the relative risk in relation to the benefit of administering SNX-111 in accordance with the current Warner-Lambert protocol," Neurex said. The company noted that treating patients with head trauma "is particularly difficult as they often have other multiple and serious injuries."